Real world effectiveness of Mycophenolate-sodium therapy in patients at risk with Graves' orbitopathy.

ABSTRACT:

Purpose

Patients with active, moderate-to-severe Graves' orbitopathy require immunosuppressive treatments to reduce inflammation and morbidity. Since 2021 EUGOGO lists Mycophenolate-sodium (MPS) as first-line-treatment, which lead to a change in treatment regimens. In our center MPS was administered mainly for patients at risk for deterioration (e.g. unstable thyroid function, smoker etc.) or as second-line treatment. To augment the limited data we analyzed our real-world cohort retrospectively.

Methods

We analyzed all consecutive patients of our tertiary referral center (2019-2023) with a complete data set, who either received MPS simultaneously with intravenous methylprednisolone (IVMP), or after a first course of IVMP.

Results

We evaluated the data of 172 patients.

SUBMITTER: Sander J 

PROVIDER: S-EPMC12486492 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature